Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...
Rare / orphan disease drugs
Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...
Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis
German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...
Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...
4B Technologies Raises RMB 100M in Pre-Series B Financing Round
China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...
RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...
Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA
The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...
Everest Medicines’ Nefecon Gains Accelerated Approval in Taiwan and South Korea
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan...
China Releases Third Batch of VAT Discounts for Anti-Tumor and Rare Disease Drugs
The Ministry of Finance, General Administration of Customs, State Taxation Administration, and National Medical Products...
Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...
AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...
RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...
Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...
Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China
The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit...
Reforgene Medicine RM-001 Thalassemia Gene Editing
China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round
Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...
RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...